STM publisher Elsevier has announced that its Gold Standard Drug Database (GSDD) has incorporated the pricing data for the federal government’s new drug pricing benchmark, Affordable Care Act Federal Upper Limit (ACA-FUL), on the same day the government made it available, enabling Elsevier GSDD customers to react quickly to any indication of price movement.
Through TRUE Daily UpdatesTM, available exclusively from Elsevier, customers can access all pertinent information on the same day that new drug launches or an important change is announced, such as the ACA-FUL, to avoid dispensing delays and potential risks to patient safety.
ACA-FUL uses Average Manufacturer Price (AMP) data, which is reported monthly and quarterly after the fact. By the time CMS aggregates AMP data and publishes new ACA-FULs, they are based on data that are three to four months old. It is estimated that there is a 60-90 day lag from the time a drug is purchased to the time an actual ACA-FUL price is published. Also, AMP can be changed per market share agreements based on rebates, causing additional price changes to happen within the 60-90 day lag time. This can have a significant impact, such as when new generics enter the market and it takes several months to calculate the ACA-FUL and additional time to calculate any changes to the AMP.
Brought to you by Scope e-Knowledge Center, a world-leading provider of metadata services, abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
